| |
| |
| |
Centre for Policy on Ageing | |
 | |
|
Alzheimer's disease in the United Kingdom
— burden of disease and future care | | Author(s) | Nick Bosanquet, Julia May, Neil Johnson |
| Corporate Author | Health Policy Unit, Imperial College of Science |
| Publisher | Imperial College of Science, London, 1998 |
| Pages | 64 pp (Health policy review paper no 12) |
| Source | CNS Business Unit, Novartis Pharmaceuticals UK Ltd, Frimley Business Park, Frimley, Camberley, Surrey GU16 5SG. |
| Keywords | Dementia ; Costs [care] ; Policy ; Services ; Care homes ; Health services ; Community care ; Family care ; United Kingdom. |
| Annotation | Alzheimer's disease (AD) is an increasingly common disorder which is costly both in terms of financial expenditure and in terms of the quality of life of the sufferers and their carers. This discussion paper looks at published information on both the clinical and economic burdens of AD in the United Kingdom (UK), and draws on this to explore the future of AD care, including the cost of care, and the implications for patients, carers and those who pay. Findings suggest that financial costs vary according to setting of care, with institutional care carrying the highest costs. The advent of new symptomatic drug therapy may mean that some AD patients can remain in their own homes, which would reduce some of the burden of AD in terms of institutional care avoided and in terms of improvements in quality of life for people with AD and their carers. (AKM). |
| Accession Number | CPA-980721201 B |
| Classmark | EA: QDC: QAD: I: KW: L: PA: P6:SJ: 8 |
Data © Centre for Policy on Ageing |
|
| ...from the Ageinfo database published by Centre for Policy on Ageing. |
| |
|
|